| Id: | acc0596 |
| Group: | 1sens |
| Protein: | IRF3 |
| Gene Symbol: | Irf3 |
| Protein Id: | P70671 |
| Protein Name: | IRF3_MOUSE |
| PTM: | phosphorylation |
| Site: | Ser396 |
| Site Sequence: | ISNSQPISLTSDQYKAYLQDL |
| Disease Category: | Cancer |
| Disease: | Colorectal Cancer |
| Disease Subtype: | Colon Cancer |
| Disease Cellline: | MC38 |
| Disease Info: | |
| Drug: | ionizing radiation |
| Drug Info: | - |
| Effect: | increase |
| Effect Info: | "Vancomycin reduces the butyric acid level by decreasing butyric acid - producing bacteria, relieves its inhibition on the phosphorylation of TBK1 and IRF3, thereby enhancing the expression of type I interferon (IFN - I) mediated by the STING pathway, promoting the anti - tumor immune response of CD8+ T cells, and improving the efficacy of ionizing radiation (IR) therapy." |
| Note: | |
| Score: | 5.0 |
| Pubmed(PMID): | 33496784 |
| Sentence Index: | 33496784_6 |
| Sentence: | "Local butyrate inhibited STING-activated type I IFN expression in dendritic cells (DCs) through blockade of TBK1 and IRF3 phosphorylation, which abrogated IR-induced tumor-specific cytotoxic T cell immune responses without directly protecting tumor cells from radiation." |
Sequence & Structure:
METPKPRILPWLVSQLDLGQLEGVAWLDESRTRFRIPWKHGLRQDAQMADFGIFQAWAEASGAYTPGKDKPDVSTWKRNFRSALNRKEVLRLAADNSKDPYDPHKVYEFVTPGARDFVHLGASPDTNGKSSLPHSQENLPKLFDGLILGPLKDEGSSDLAIVSDPSQQLPSPNVNNFLNPAPQENPLKQLLAEEQWEFEVTAFYRGRQVFQQTLFCPGGLRLVGSTADMTLPWQPVTLPDPEGFLTDKLVKEYVGQVLKGLGNGLALWQAGQCLWAQRLGHSHAFWALGEELLPDSGRGPDGEVHKDKDGAVFDLRPFVADLIAFMEGSGHSPRYTLWFCMGEMWPQDQPWVKRLVMVKVVPTCLKELLEMAREGGASSLKTVDLHISNSQPISLTSDQYKAYLQDLVEDMDFQATGNI
Select PDB:
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| S | 396 | U | Experimental autoimmune encephalomyelitis | Phosphorylation | 33710283 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
